@article{41db6bdf48314e75aba9680c8805c613,
title = "Late-Life Depression Is Associated With Reduced Cortical Amyloid Burden: Findings From the Alzheimer's Disease Neuroimaging Initiative Depression Project",
abstract = "Background: We evaluated the role of cortical amyloid deposition as a factor contributing to memory dysfunction and increased risk of dementia associated with late-life depression (LLD). Methods: A total of 119 older adult participants with a current diagnosis of major depression (LLD) from the Alzheimer's Disease Neuroimaging Initiative (ADNI) Depression Project study and 119 nondepressed (ND) cognitively unimpaired participants matched on age, sex, and APOE genotype were obtained from the ADNI database. Results: Thirty-three percent of LLD participants met ADNI criteria for mild cognitive impairment. Compared with ND individuals, the LLD group exhibited less global amyloid beta (Aβ) accumulation (p = .05). The proportion of amyloid positivity in the LLD group was 19.3% compared with 31.1% for the ND participants (p = .02). Among LLD participants, global Aβ was not associated with lifetime number of depressive episodes, lifetime length of depression, length of lifetime selective serotonin reuptake inhibitor use, or lifetime length of untreated depression (p >. 21 for all). Global Aβ was associated with worse memory performance (p = .05). Similar results were found in secondary analyses restricting comparisons to the cognitively unimpaired LLD participants as well as when comparing the LLD group with an ND group that included participants with mild cognitive impairment. Conclusions: Contrary to expectation, the LLD group showed less Aβ deposition than the ND group and Aβ deposition was not associated with depression history characteristics. Aβ was associated with memory, but this relationship did not differ between LLD and ND. Our results suggest that memory deficits and accelerated cognitive decline reported in previous studies of LLD are not due to greater cortical Aβ accumulation.",
keywords = "Alzheimer's disease, Amyloid, Cognition, Depressive symptoms, Late-life depression, Mild cognitive impairment",
author = "{Alzheimer{\textquoteright}s Disease Neuroimaging Initiative and the ADNI Depression Project} and Mackin, {R. Scott} and Insel, {Philip S.} and Susan Landau and David Bickford and Ruth Morin and Emma Rhodes and Duygu Tosun and Rosen, {Howie J.} and Meryl Butters and Paul Aisen and Rema Raman and Andrew Saykin and Arthur Toga and Clifford Jack and Robert Koeppe and Weiner, {Michael W.} and Craig Nelson",
note = "Funding Information: RSM has received research support from the National Institute of Mental Health and Johnson and Johnson. SL has received research support from the National Institute on Aging and has consulted for NeuroVision and Cortexyme. RR has received research support from the National Institute on Aging, Eli Lilly, and Janssen. MWW has served on the scientific advisory boards for Pfizer, BOLT International, Neurotrope Bioscience, Alzheon, the Alzheimer{\textquoteright}s Therapeutic Research Institute, Eli Lilly, the University of Pennsylvania{\textquoteright}s Neuroscience of Behavior Initiative, the National Brain Research Centre (India), Dolby Family Ventures, and ADNI. CN has been an advisor or consultant to Assurex, Eiasi, FVS-7, and Janssen. The other authors report no biomedical financial interests or potential conflicts of interest. Funding Information: Data collection and sharing for this project was funded by the Alzheimer{\textquoteright}s Disease Neuroimaging Depression project (ADNI-D) ( National Institute of Mental Health Grant No. R01098062 ) and the ADNI ( National Institutes of Health Grant No. U01 AG024904 ). Funding Information: Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Depression project (ADNI-D) (National Institute of Mental Health Grant No. R01098062) and the ADNI (National Institutes of Health Grant No. U01 AG024904). We acknowledge the Ray and Dagmar Dolby Family Fund for research support and Avid Radiopharmaceuticals for providing florbetapir for this study. Data used in preparation of this article were obtained from the ADNI-D and ADNI databases (www.loni.usc.edu). As such, the investigators within the ADNI-D and ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI-D and ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf. ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and contributions from the following: Abbott, AstraZeneca, Bayer Schering Pharma, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corp. Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics, Johnson and Johnson, Eli Lilly and Co. Medpace, Merck and Co. Novartis, Pfizer, F. Hoffmann?La Roche, Schering-Plough, and Synarc, as well as from nonprofit partners the Alzheimer's Association and Alzheimer's Drug Discovery Foundation, with participation from the U.S. Food and Drug Administration. Private sector contributions to ADNI are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuroimaging at the University of California, Los Angeles. RSM has received research support from the National Institute of Mental Health and Johnson and Johnson. SL has received research support from the National Institute on Aging and has consulted for NeuroVision and Cortexyme. RR has received research support from the National Institute on Aging, Eli Lilly, and Janssen. MWW has served on the scientific advisory boards for Pfizer, BOLT International, Neurotrope Bioscience, Alzheon, the Alzheimer's Therapeutic Research Institute, Eli Lilly, the University of Pennsylvania's Neuroscience of Behavior Initiative, the National Brain Research Centre (India), Dolby Family Ventures, and ADNI. CN has been an advisor or consultant to Assurex, Eiasi, FVS-7, and Janssen. The other authors report no biomedical financial interests or potential conflicts of interest. Publisher Copyright: {\textcopyright} 2020",
year = "2021",
month = apr,
day = "15",
doi = "10.1016/j.biopsych.2020.06.017",
language = "English (US)",
volume = "89",
pages = "757--765",
journal = "Biological psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "8",
}